triazoles has been researched along with navitoclax in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akudugu, JM; Hamunyela, RH; Serafin, AM | 1 |
| Bianchetti, E; Halatsch, ME; Ishida, CT; Karpel-Massler, G; Shu, C; Siegelin, MD; Westhoff, MA | 1 |
| Han, X; Hu, Z; Li, Z; Wang, Y; Wu, Z; Yan, J; Zheng, Q; Zhu, Q | 1 |
| Bianchetti, E; Ishida, CT; Karpel-Massler, G; Shang, E; Shu, C; Siegelin, MD; Westhoff, MA; Zhang, Y | 1 |
| Bernards, R; Caldas, C; Chin, SF; Crown, JP; Das, S; Di Grande, A; Dowling, CM; Fan, Y; Gallagher, WM; Haley, KE; Jirström, K; Linn, S; Madden, SF; Mooney, B; Moran, B; Ní Chonghaile, T; O'Connor, DP; Rueda, OM; Tarrant, F; Varešlija, D; Walsh, L; Young, LS | 1 |
5 other study(ies) available for triazoles and navitoclax
| Article | Year |
|---|---|
Strong synergism between small molecule inhibitors of HER2, PI3K, mTOR and Bcl-2 in human breast cancer cells.
Topics: Aniline Compounds; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Drug Synergism; Humans; Imidazoles; Oxazoles; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Quinolines; Receptor, ErbB-2; Sulfonamides; TOR Serine-Threonine Kinases; Triazoles | 2017 |
BH3-mimetics and BET-inhibitors elicit enhanced lethality in malignant glioma.
Topics: Acetanilides; Aniline Compounds; Animals; Antineoplastic Agents; Apoptosis; Azepines; Bcl-2-Like Protein 11; Caspases; Cell Line, Tumor; Cell Survival; Disease Models, Animal; Drug Synergism; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Glioma; Heterocyclic Compounds, 3-Ring; Humans; Membrane Potential, Mitochondrial; Mice; Proteins; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-myc; RNA, Small Interfering; Sulfonamides; Triazoles; Xenograft Model Antitumor Assays | 2017 |
The BET-Bromodomain Inhibitor JQ1 synergized ABT-263 against colorectal cancer cells through suppressing c-Myc-induced miR-1271-5p expression.
Topics: Aniline Compounds; Apoptosis; Azepines; Base Sequence; Cell Line, Tumor; Colorectal Neoplasms; Drug Synergism; Gene Expression Regulation, Neoplastic; Humans; MicroRNAs; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-myc; Sulfonamides; Triazoles | 2017 |
Dual Inhibition of Bcl-2/Bcl-xL and XPO1 is synthetically lethal in glioblastoma model systems.
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Apoptosis; bcl-X Protein; Brain Neoplasms; Cell Proliferation; Drug Therapy, Combination; Exportin 1 Protein; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Hydrazines; Karyopherins; Mice; Mice, Nude; Proto-Oncogene Proteins c-bcl-2; Receptors, Cytoplasmic and Nuclear; Sulfonamides; Triazoles; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2018 |
BET Inhibition as a Rational Therapeutic Strategy for Invasive Lobular Breast Cancer.
Topics: Aniline Compounds; Antineoplastic Agents; Apoptosis; Azepines; Breast Neoplasms; Carcinoma, Lobular; Cell Cycle; Cell Proliferation; Cohort Studies; Female; Gene Expression Regulation, Neoplastic; Humans; Neoplasm Invasiveness; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Sulfonamides; Survival Rate; Transcription Factors; Triazoles; Tumor Cells, Cultured | 2019 |